Clinical Trial Update: Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial of telotristat etiprate (LX1606) in symptomatic carcinoid syndrome completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Syndrome

Drugs mentioned

• Telotristat Etiprate (telotristat etiprate)

Snippet

Sponsor: Lexicon Pharmaceuticals | Conditions: Carcinoid Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2018-04-06